ClinicalTrials.gg

Respiratory Distress Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,388 studies for Respiratory Distress Syndrome across more than 10 countries. 281 are recruiting or about to start. 906 of them are mainly about Respiratory Distress Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its 4 narrower conditions too, such as Respiratory Distress Syndrome, Newborn: 1,553 studies, 313 open.

ClinicalTrials.gov finds 1,938 studies for Respiratory Distress Syndrome. How that becomes 1,388 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Respiratory Distress Syndrome, and those it files under no condition that list Respiratory Distress Syndromethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,938Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −164Filed under a narrower condition, counted on its own pageRespiratory Distress Syndrome, Newborn 95 · Transient Tachypnea of the Newborn 27 · Respiratory Distress Syndrome In Premature Infants 18 · Hyaline Membrane Disease 14
  3. −148List Respiratory Distress Syndrome as a condition, but the registry did not file them under itMost often written as “ARDS (Acute Respiratory Distress Syndrome)” (48), “COVID-19 Acute Respiratory Distress Syndrome” (43), and “Respiratory Distress Syndrome in Premature Infant” (22). The registry filed them under other conditions only, most often Acute Lung Injury (56) and COVID-19 (47).
  4. −238Match it another way161 name it in the title, 8 in a keyword, and 69 by a synonym or other text the search reads.
  5. 1,388The count on this page42 of them list Respiratory Distress Syndrome in their own words; the registry filed them under no condition.

Status

Completed
655
Status unknown
218
Recruiting
196
Terminated
133
Not yet recruiting
72
Withdrawn
70

Phase

Phase 2
216
Phase 3
129
Phase 1
99
Phase 4
47
Early Phase 1
5

Where

United States
324
France
217
China
146
Italy
91
Canada
67
Spain
62

Who develops what

Add Respiratory Distress Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 17 programs from 11 companies, 14 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare ImmunityBio and Staidson (Beijing) Biopharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Supportive CareRecent, limited
Evidence
  • NCT06640777 · LEAF4Life, Inc. · Phase 3 · live · background · “Supportive Care” · registered Aug 2024
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
APC-0101☆ Track1 live phase-3 study: NCT06776783Aerogen Pharma Limited
Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC.☆ Track1 live phase-3 study: NCT07479043Breathe Biologics, Inc.
greziprubart☆ Track1 live phase-3 study: NCT07208591Staidson (Beijing) Biopharmaceuticals Co., Ltd

The 3 in phase 3 with the nearest primary completion, of 17 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.YD0743 · Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Phase 2 named, not the main aimNCT07413094 Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS — primary endpoint: Number of Ventilator-Free Days · 309 enrolled
  • May 2027 est.APC-0101 · Aerogen Pharma Limited · Phase 3 main aimNCT06776783 Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome — primary endpoint: Failure Criteria · 520 enrolled
  • 31 Oct 2027 est.Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC. · Breathe Biologics, Inc. · Phase 3 main aimNCT07479043 To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). — primary endpoint: Proportion of Participants Alive and Free of Respiratory Failure · 128 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Respiratory Distress Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 7 open · Inhaled anesthetics 2 open · Tyrosine kinase inhibitors (TKIs) 2 open · Opioids 2 open · Neuromuscular blockers 1 open

Coming up

97studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 117 (60%) set no upper age limit and 49 (25%) stop at 75 or younger. 51 (26%) take children under 18. 4 (2%) are for women only and 0 (0%) for men only; 9 (5%) take healthy volunteers.

Recruiting studies that take each age, of 196
AgeWomenMen
1019 (10%)18 (9%)
18157 (80%)155 (79%)
30159 (81%)155 (79%)
40158 (81%)156 (80%)
50159 (81%)157 (80%)
65157 (80%)155 (79%)
75152 (78%)150 (77%)
85136 (69%)134 (68%)

Across all 1,388 studies, recruiting or not: 26% stop at 75 or younger and 22% at 65; 28% take children; 1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Respiratory Distress Syndrome studies take

Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 1/219 mo11–23 · 25 studies——
Phase 218 mo9–41 · 59 studies—18 mo9–44 · 31 studies
Phase 329 mo14–46 · 39 studies——
Interventional, no phase24 mo12–42 · 273 studies—24 mo12–42 · 266 studies
Observational24 mo12–49 · 234 studies—24 mo12–47 · 228 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,388. Browse all 1,388 → or search them.